Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 201 - 220 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
What Happens If AstraZeneca Launches Epanova? A Look at How Amarin?s IP May Give It the Upper Hand
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Updated Revenue Guidance Consistent With Proprietary OM-3 Survey; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Confidence in Vascepa Growth Reaffirmed by Proprietary 100-Physician Survey; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
We initiate coverage with a Buy rating and $31/share price target
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Positive Revenue and Expansion Opportunities Met With Conservative Guidance, in our View; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Shifting Aspects of CV Risk Reduction Landscape, As Vascepa sNDA Submitted to FDA; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Positive REDUCE-IT Results Presented at American College of Cardiology 2019 Meeting; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Expect the Continued Underlying Vascepa Demand to Drive Value; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Takeaways From the Amarin Management Breakfast During the 2019 JPM Healthcare Conference; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
In Anticipation of AHA, We Reit Buy and Raise PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
REDUCE-IT Results Even Stronger than Our Best Case Scenario; Reit Buy and Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Favorable Risk/Return Profile Ahead of REDUCE-IT Topline; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2018 Ought to Mark End of a Long Journey (or a New Beginning); Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
3Q Update: Getting Our Ducks in a Row Ahead of REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
We Believe There Is Now an Attractive Entry Point Heading Into Interim Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
CANTOS Study Further Validates Mechanism and Commercial Upside to REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A